Tier 4 — mechanistic

A critical examination of human data for the biological activity of quercetin and its phase-2 conjugates

Gary Williamson, Michael N Clifford
Critical reviews in food science and nutrition 2025 65(9):1669-1705

Bibliography

PubMed
PMID 38189312
DOI
10.1080/10408398.2023.2299329
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignCritical review of human exposure and metabolite bioactivity
ModelNarrative or mixed evidence review
SampleClinical interventions, feeding studies, and cell experiments; no new cohort
InterventionQuercetin phase-2 conjugates at dietary or supplemental exposures
DurationLiterature available at publication
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2025, this source examined forms, absorption and food sources. Its evidence base was Clinical interventions, feeding studies, and cell experiments; no new cohort. It evaluated Quercetin phase-2 conjugates at dietary or supplemental exposures across Literature available at publication.

Circulating conjugates and local deconjugation may help explain biological activity, but evidence at ordinary dietary concentrations remains sparse.

Cell effects at selected concentrations do not reliably predict clinical benefit. Human metabolite variation and tissue exposure remain important unresolved issues.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Circulating conjugates and local deconjugation may help explain biological activity, but evidence at ordinary dietary concentrations remains sparse.
  • The recorded outcome domains were Exposure and pharmacokinetics.

What this study can and cannot tell us

  • Cell effects at selected concentrations do not reliably predict clinical benefit. Human metabolite variation and tissue exposure remain important unresolved issues.
  • The conclusions inherit the limitations of the underlying studies. A narrative interpretation or guideline recommendation is not a new randomized treatment comparison.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025
Tier 4
Enzymatically Modified Isoquercitrin: Production, Metabolism, Bioavailability, Toxicity, Pharmacology, and Related Molecular Mechanisms
Aleksandra Owczarek-Januszkiewicz et al. · International journal of molecular sciences · 2022
Tier 4
Recent advances on the improvement of quercetin bioavailability
Kevser Kandemir et al. · Trends in Food Science & Technology · 2022
Tier 2
Bioavailability of Quercetin in Humans with a Focus on Interindividual Variation
A Filipa Almeida et al. · Comprehensive reviews in food science and food safety · 2018

Citation network

Articles citing this research paper

5 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology